Healthcare News
- 2013-05-20 Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
2013-05-20
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
- 2013-05-17 Bayer European Regulatory update on Diane-35
2013-05-17
Bayer European Regulatory update on Diane-35
Bayer HealthCare Pharmaceuticals welcomes the statement of the Product Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) affirming the positive benefit-risk profile of Diane-35 provided that several measures are implemented to minimize the risk of thromboembolism. more
- 2013-05-17 Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
2013-05-17
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) for regulatory approval in Japan. more




